Cohen–Boyer recombinant DNA patents
E915626
The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Cohen–Boyer recombinant DNA patents canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T11290983 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Cohen–Boyer recombinant DNA patents Context triple: [Stanley N. Cohen, knownFor, Cohen–Boyer recombinant DNA patents]
-
A.
Bayh–Dole Act
The Bayh–Dole Act is a landmark 1980 U.S. law that allows universities, small businesses, and other institutions to retain ownership of inventions developed with federal funding, spurring technology transfer and commercialization.
-
B.
Technical Corrections to the Bayh–Dole Act
Technical Corrections to the Bayh–Dole Act is a legislative measure that refined and clarified the original Bayh–Dole Act’s provisions governing the ownership and commercialization of inventions arising from federally funded research.
-
C.
CRISPR-Cas9 gene-editing technology
CRISPR-Cas9 gene-editing technology is a revolutionary molecular tool that allows scientists to precisely modify DNA within living organisms, transforming research, medicine, and biotechnology.
-
D.
Association for Molecular Pathology v. Myriad Genetics, Inc.
Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
-
E.
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure
The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure is an international agreement that standardizes how deposits of microorganisms are recognized for patent applications, allowing a single deposit at an approved authority to be accepted by all member states.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Cohen–Boyer recombinant DNA patents Target entity description: The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
-
A.
Bayh–Dole Act
The Bayh–Dole Act is a landmark 1980 U.S. law that allows universities, small businesses, and other institutions to retain ownership of inventions developed with federal funding, spurring technology transfer and commercialization.
-
B.
Technical Corrections to the Bayh–Dole Act
Technical Corrections to the Bayh–Dole Act is a legislative measure that refined and clarified the original Bayh–Dole Act’s provisions governing the ownership and commercialization of inventions arising from federally funded research.
-
C.
CRISPR-Cas9 gene-editing technology
CRISPR-Cas9 gene-editing technology is a revolutionary molecular tool that allows scientists to precisely modify DNA within living organisms, transforming research, medicine, and biotechnology.
-
D.
Association for Molecular Pathology v. Myriad Genetics, Inc.
Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
-
E.
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure
The Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure is an international agreement that standardizes how deposits of microorganisms are recognized for patent applications, allowing a single deposit at an approved authority to be accepted by all member states.
- F. None of above. chosen
Statements (40)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology patent
ⓘ
foundational patent ⓘ recombinant DNA patent ⓘ university-owned patent ⓘ |
| assignee |
Stanford University
NERFINISHED
ⓘ
University of California NERFINISHED ⓘ |
| commercialModel | non-exclusive licensing ⓘ |
| countryOfPatent | United States NERFINISHED ⓘ |
| describedMethod |
cloning of recombinant DNA in bacteria
ⓘ
creation of recombinant DNA molecules ⓘ insertion of DNA fragments into plasmid vectors ⓘ use of DNA ligase to join DNA fragments ⓘ use of restriction endonucleases to cut DNA ⓘ |
| enabledIndustry | biotechnology industry ⓘ |
| enabledTechnology |
modern genetic engineering
ⓘ
recombinant DNA technology ⓘ |
| field |
biotechnology
ⓘ
genetic engineering ⓘ molecular biology ⓘ |
| historicalSignificance |
considered among the most important patents in biotechnology
ⓘ
marked the beginning of large-scale commercialization of academic molecular biology research ⓘ |
| impact |
became a model for university technology licensing
ⓘ
established a broad platform for DNA cloning methods ⓘ facilitated commercialization of recombinant DNA research ⓘ |
| influenced |
subsequent biotechnology patent strategies
ⓘ
university–industry technology transfer practices ⓘ |
| inventor |
Herbert W. Boyer
NERFINISHED
ⓘ
Stanley N. Cohen NERFINISHED ⓘ |
| jurisdiction | United States Patent and Trademark Office NERFINISHED ⓘ |
| licenseType | royalty-bearing license ⓘ |
| namedAfter |
Herbert W. Boyer
NERFINISHED
ⓘ
Stanley N. Cohen NERFINISHED ⓘ |
| relatedTo |
DNA ligase
NERFINISHED
ⓘ
plasmid cloning vectors ⓘ recombinant DNA ⓘ restriction enzymes ⓘ |
| timePeriod | 1970s ⓘ |
| usedIn |
development of genetically engineered microorganisms
ⓘ
development of therapeutic biologics ⓘ production of recombinant proteins ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Cohen–Boyer recombinant DNA patents Description of subject: The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.